NCT04771455 is a NA clinical trial of Behavioral weight loss in Obesity, sponsored by Northwestern University.

Who is sponsoring NCT04771455?

NCT04771455 is sponsored by Northwestern University.

What drugs are being tested in NCT04771455?

Interventions in NCT04771455: Behavioral weight loss, Intervention component: Decrease overvaluation of weight and shape, Intervention component: Decrease unhealthy weight control practices, Intervention component: Decrease negative affect.

What condition does NCT04771455 study?

NCT04771455 studies Obesity, Binge Eating.

Is NCT04771455 still recruiting?

NCT04771455 is currently completed. Last updated 19 September 2024.

Are results published for NCT04771455?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-09-19 · How we verify

NCT04771455

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Testing Intervention Strategies for Addressing Obesity and Binge Eating

Completed NA Results posted Last updated 19 September 2024

What this trial tests

NA trial testing Behavioral weight loss in Obesity in 81 participants. Completed in 30 November 2022.

Timeline

16 February 2021

Primary endpoint
30 November 2022

30 November 2022

Quick facts

Lead sponsor	Northwestern University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	factorial
Masking	single
Primary purpose	treatment
Enrollment	81
Start date	16 February 2021
Primary completion	30 November 2022
Estimated completion	30 November 2022
Sites	1 location across United States

Drugs / interventions tested

Behavioral weight loss
Intervention component: Decrease overvaluation of weight and shape
Intervention component: Decrease unhealthy weight control practices
Intervention component: Decrease negative affect

Conditions studied

Obesity — all drugs for Obesity →
Binge Eating — all drugs for Binge Eating →

Sponsor

Northwestern University

Who can join

18 and older, any sex, with Obesity or Binge Eating. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Weight Primary · Measured at baseline, post-intervention (16-weeks)

Changes in weight

Group	Value	95% CI
Overvaluation of Weight/Shape (Yes)	4.2	± 21.9
Overvaluation of Weight/Shape (no)	6.9	± 21.3
Unhealthy Weight Control Practices (Yes)	4.7	± 22.6
Unhealthy Weight Control Practices (no)	6.3	± 20.7
Negative Affect (Yes)	8.5	± 27.7
Negative Affect (no)	2.7	± 12.6

Binge Eating Episodes Primary · Measured at baseline, post-intervention (16-weeks)

Changes in episodes of binge eating (past 28 days)

Group	Value	95% CI
Overvaluation of Weight/Shape (Yes)	8.1	± 10.9
Overvaluation of Weight/Shape (no)	10.1	± 13.7
Unhealthy Weight Control Practices (Yes)	6.9	± 8.5
Unhealthy Weight Control Practices (no)	11.2	± 15.0
Negative Affect (Yes)	9.8	± 11.1
Negative Affect (no)	8.4	± 13.5

Sponsor's own description

The purpose of this study is to conduct a randomized pilot trial of a mobile intervention that targets obesity and binge eating.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Other Northwestern University trials

Trials by the same sponsor.

NCT06545695 — Epidermal Growth Factor Receptor Inhibition for Keratinopathies · Phase 1, PHASE2 · not yet recruiting
NCT07261657 — N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive C · EARLY_PHASE1 · not yet recruiting
NCT07392775 — ALDH2 Genetic Testing in East Asian Community · NA · not yet recruiting
NCT06886776 — Implementing A Secure Firearm Storage Program in Illinois Health Centers in Partnership With AllianceChicago and the Ill · NA · not yet recruiting
NCT07469176 — Co-Designing and Evaluating Additional Mothers and Babies Program Content for Expectant and New Parents of Children With · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04771455 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Northwestern University
Last refreshed: 19 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04771455.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing